Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care

Open access
Kast, Richard E., Boockvar, John A., Brüning, Ansgar, Cappello, Francesco, Chang, Wen-Wei, Cvek, Boris, Dou, Q. Ping, Duenas-Gonzalez, Alfonso, Efferth, Thomas, Focosi, Daniele, Ghaffari, Seyed H., Karpel-Massler, Georg, Ketola, Kirsi, Khoshnevisan, Alireza, Keizman, Daniel, Magné, Nicolas, Marosi, Christine, McDonald, Kerrie, Muñoz, Miguel, Paranjpe, Ameya, Pourgholami, Mohammad H., Sardi, Iacopo, Sella, Avishay, Srivenugopal, Kalkunte S., Tuccori, Marco, Wang, Weiguang, Wirtz, Christian R., Halatsch, Marc-Eric·2013·Oncotarget

Abstract

// Richard E. Kast 1 , John A. Boockvar 2 , Ansgar Brüning 3 , Francesco Cappello 4 , Wen-Wei Chang 5 , Boris Cvek 6 , Q. Ping Dou 7 , Alfonso Duenas-Gonzalez 8 , Thomas Efferth 9 , Daniele Focosi 10 , Seyed H. Ghaffari 11 , Georg Karpel-Massler 12 , Kirsi Ketola 13 , Alireza Khoshnevisan 14 , Daniel Keizman 15 , Nicolas Magné 16 , Christine Marosi 17 , Kerrie McDonald 18 , Miguel Muñoz 19 , Ameya Paranjpe 20 , Mohammad H. Pourgholami 18 , Iacopo Sardi 21 , Avishay Sella 22 , Kalkunte S. Srivenugopal 20 , Marco Tuccori 10 , Weiguang Wang 23 , Christian R. Wirtz 12 , Marc-Eric Halatsch 12 1 IIAIGC Headquarters, Dean of Studies, Burlington, VT, USA 2 Weill Cornell Medical College, NY, USA 3 University of München, München, Germany 4 University of Palermo, Palermo, Italy 5 Chung Shan Medical University Hospital, Taichung, Taiwan 6 Palacky University, Olomouc, Czech Republic 7 Wayne State University, Detroit, USA 8 Instituto de Investigaciones Biomedicas UNAM, Instituto Nacional de Cancerología, Mexico City, Mexico 9 Johannes Gutenberg University, Mainz, Germany 10 University of Pisa, Pisa, Italy 11 Tehran University of Medical Sciences, Tehran, Iran 12 University of Ulm, Ulm, Germany 13 University of British Columbia, Vancouver, Canada 14 Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran 15 Oncology Department, Meir Medical Center, Tel Aviv University, Israel 16 Institut de Cancérologie Lucien Neuwirth, Saint-Priest en Jarez, France 17 Medical University of Vienna, Wein, Austria 18 University of New South Wales, Sydney, Australia 19 Virgen del Rocío University Hospital, Sevilla, Spain 20 Texas Tech University Health Sciences Center, Amarillo, USA 21 Meyer Children’s Hospital, Firenze, Italy 22 Assaf Harofeh Medical Center, Zerifin, Israel 23 University of Wolverhampton, Wolverhampton, UK Correspondence: Richard E. Kast , email: // Marc-Eric Halatsch , email: // Keywords : angiotensin, aprepitant, artesunate, auranofin, captopril, cytokines, disulfiram, glioblastoma, ketoconazole, nelfinavir, neurokinin, sertraline, temozolomide Received : April 7, 2013 Accepted : April 11, 2013 Published : April 13, 2013 Abstract To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed and used for other non-cancer indications. Focus was on adding drugs which met these criteria: a) were pharmacologically well characterized, b) had low likelihood of adding to patient side effect burden, c) had evidence for interfering with a recognized, well-characterized growth promoting element of glioblastoma, and d) were coordinated, as an ensemble had reasonable likelihood of concerted activity against key biological features of glioblastoma growth. We found nine drugs meeting these criteria and propose adding them to continuous low dose temozolomide, a currently accepted treatment for relapsed glioblastoma, in patients with recurrent disease after primary treatment with the Stupp Protocol. The nine adjuvant drug regimen, Coordinated Undermining of Survival Paths, CUSP9, then are aprepitant, artesunate, auranofin, captopril, copper gluconate, disulfiram, ketoconazole, nelfinavir, sertraline, to be added to continuous low dose temozolomide. We discuss each drug in turn and the specific rationale for use- how each drug is expected to retard glioblastoma growth and undermine glioblastoma’s compensatory mechanisms engaged during temozolomide treatment. The risks of pharmacological interactions and why we believe this drug mix will increase both quality of life and overall survival are reviewed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.969

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 167

Metadata

Authors
Kast, R. E., Boockvar, J. A., Brüning, A., Cappello, F., Chang, W.-W., Cvek, B., Dou, Q. P., Duenas-Gonzalez, A., Efferth, T., Focosi, D., Ghaffari, S. H., Karpel-Massler, G., Ketola, K., Khoshnevisan, A., Keizman, D., Magné, N., Marosi, C., McDonald, K., Muñoz, M., Paranjpe, A., Pourgholami, M. H., Sardi, I., Sella, A., Srivenugopal, K. S., Tuccori, M., Wang, W., Wirtz, C. R., & Halatsch, M.-E.
Venue
Oncotarget
Published
2013-04-13
Volume
4
Issue
4
Pages
502-530
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2112740677
Cited by
167
References
6
FWCI
9.91
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.